Findings are based on a systematic review and meta-analysis of 25 trials involving 26,478 patients with chronic kidney disease (CKD) with or without dialysis. Cardiovascular safety seems similar between hypoxia inducible factor prolyl hydroxylase inhibitors (HIF-PHI), erythropoiesis-stimulating agents (ESA).
An award-winning genomic assay for measuring HER2 mRNA expression could help predict treatment responses in advanced HER2+ breast cancer and ultimately guide clinical decision-making, suggests study.